trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'destiny,crc,02', 'thanks']
thanks to dr kanwal pratap singh raghav, of , for sitting down with us during to talk about primary results from the destiny-crc02 study! head to our site for more exclusive #asco23 coverage! #crcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.